A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )

This trial tests a new experimental drug called CT1190B in people with blood cancers — specifically lymphomas and leukemias — that have returned or stopped responding to previous treatments. The study aims to find the right dose and assess how safe and effective the drug is. **You may be eligible if...** - You have a relapsed or refractory blood cancer (lymphoma or leukemia) that has not responded to standard treatments - You have tried at least one prior treatment - Your overall health and organ function are adequate to receive the experimental drug - You are 18 or older **You may NOT be eligible if...** - You have active brain involvement by your cancer - You have a serious uncontrolled infection - You have significant heart, liver, or kidney disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.